Modi S, Tsurutani J, Takahashi S. et al. Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers. Cancer Res 2018; 78: Abstr.. PD3-07
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.